Beam Therapeutics (BEAM) Current Assets (2019 - 2026)

Beam Therapeutics (BEAM) has reported Current Assets for 8 consecutive years, with $1.3 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Assets rose 1.55% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (up 1.55% YoY), while the FY2025 annual figure was $1.3 billion, up 44.47% from the prior year.
• Current Assets steadied at $1.3 billion in Q1 2026 per BEAM's latest filing, from $1.3 billion in the prior quarter.
• Across five years, Current Assets topped out at $1.3 billion in Q4 2025 and bottomed at $878.1 million in Q4 2024.
• Historically, Current Assets has averaged $1.1 billion across 5 years, with a median of $1.1 billion in 2022.
• Annual changes were most pronounced in 2022 — Current Assets surged 140.87% — and 2024, when it fell 27.49%.
• Beam Therapeutics' Current Assets stood at $1.1 billion in 2022, then increased by 10.81% to $1.2 billion in 2023, then dropped by 27.49% to $878.1 million in 2024, then surged by 44.47% to $1.3 billion in 2025, then fell by 0.14% to $1.3 billion in 2026.
• Business Quant data shows BEAM's Current Assets at $1.3 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.1 billion in Q3 2025.